Companies: 10,795·Total market cap: $144.5T
iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc.

ITOSNASDAQHealthcare
$10.15
+$0.02(+0.20%)
Market Cap$448684810
P/E Ratio
52W High$17.63
52W Low$4.8

iTeos Therapeutics, Inc. (ITOS) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

itos · stock forecast · 8 analysts (3M) · FMP · updated Oct 17, 2025

Analyst Rating & Consensus

Based on 8 Wall Street analysts in the past 3 months

SellBuy

Hold

8 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
3
Hold
5
Sell
0
Strong Sell
0
Total: 8 · Buy rate: 37.5%

12-Month Price Target

High

$46.00

Consensus

$18.20

+79.3% upside

Low

$9.00

Median: $12 · Last Close: $10.15

The iTeos Therapeutics, Inc. (ITOS) analyst consensus is Hold, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month ITOS price target is $18.20, representing +79.3% upside from the current price of $10.15.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $18 (79.3%)

Consensus Target

$18.20

79.3% upside

High Target

$46

353.2%

Low Target

$9

-11.3%

Current Price

$10.15

as of today

Based on analyst price targets, the ITOS stock price prediction for the next 12 months ranges from $9 to $46. The consensus ITOS price forecast of $18.20 implies 79.3% upside from the current price of $10.15.

Short-Term Price Prediction

Ranging

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$10.140.06%

1-day model range: $10.14–$10.15. Peak: $10.15 (-0.06%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$5-50.0%
2028$4-63.7%
2029$3-69.2%
2030$3-71.8%
2031-73.1%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

86%7%7%
12Buy
1Neutral
1Sell
RSI (14)58.3Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · ITOS · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$10.14BUY
MA 10$10.15SELL
MA 20$10.13BUY
MA 50$10.14BUY
MA 100$9.08BUY
MA 200$8.29BUY
Current $ITOS · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$10.15BUY
EMA 10$10.15BUY
EMA 20$10.14BUY
EMA 50$9.93BUY
EMA 100$9.44BUY
EMA 200$9.40BUY
Current $ITOS · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Wells Fargo2025-08-07
Maintains
Equal WeightEqual Weight
Wedbush2025-05-28
Downgrade ↓
OutperformNeutral
Wells Fargo2025-05-28
Downgrade ↓
OverweightEqual Weight
HC Wainwright & Co.2025-05-14
Downgrade ↓
BuyNeutral
Leerink Partners2025-05-14
Downgrade ↓
OutperformMarket Perform
Piper Sandler2025-05-14
Maintains
OverweightOverweight
Wells Fargo2025-05-14
Maintains
OverweightOverweight
JP Morgan2025-05-13
Downgrade ↓
OverweightNeutral
Wells Fargo2025-04-29
Maintains
OverweightOverweight
HC Wainwright & Co.2025-03-06
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on iTeos Therapeutics, Inc. (ITOS) stock. Of the recent 40 rating actions, 0 were upgrades and 5 were downgrades. 8 analysts currently cover ITOS.

Analyst Recommendation Trends

Buy ratings202
Hold ratings01↑ +1
Sell ratings00

ITOS analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$-8M

↓ 110.5% YoY

Revenue Next Year

$7M

↓ 183.8% YoY

EPS This Year

$-3.72

EPS Next Year

$-2.00

↓ 46.1% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast ITOS EPS of $-3.72 for the current fiscal year, based on estimates from 2 analysts. The ITOS revenue forecast is $-8M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The ITOS stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ITOS price target is $18.20 (+79.3% upside), with an analyst consensus of Hold.

The ITOS short-term stock prediction for tomorrow is $10.14 (-0.06%). The ITOS stock price prediction for 2027 estimates an average of $5. The ITOS stock prediction for 2030 projects a range of $3–$3.

iTeos Therapeutics, Inc. trades on NASDAQ under the ticker ITOS. The ITOS stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 38% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

ITOS forecast · 8 questions

According to 8 Wall Street analysts, the average 12-month ITOS price target is $18.20, with a high forecast of $46.00 and a low of $9.00. The median price target is shown in the chart above when available. This implies +79.3% potential upside from the current price of $10.15.

ITOS price targetWhat is ITOS price targetITOS analyst price targetITOS 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.